Experimental Physiology
	

Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Physiology in Press

First published online on April 27, 2007.
Experimental Physiology (2007)
DOI: 10.1113/expphysiol.2006.036889
© The Physiological Society 2007
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iliff, J. J.
Right arrow Articles by Alkayed, N. J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iliff, J. J.
Right arrow Articles by Alkayed, N. J

Received March 9, 2007
Revised April 10, 2007
Accepted after revision April 24, 2007


Vascular [310]

A novel role for P450 eicosanoids in the neurogenic control of cerebral blood flow

Jeffrey John Iliff 1, Liesl N Close 1, Nathan R Selden 1, Nabil J Alkayed 1*

1 OHSU

* To whom correspondence should be addressed. E-mail: alkayedn{at}ohsu.edu.


   Abstract
The P450 eicosanoids epoxyeicosatrienoic acids (EETs) are endogenous lipid mediators produced in brain by P450 epoxygenases and metabolized through multiple pathways including soluble epoxide hydrolase (sEH). EETs play important functions in brain, including cerebral blood flow regulation and protection from ischemic brain injury. We previously demonstrated that ischemic preconditioning induces cytochrome P450 2C11 epoxygenase (CYP2C11) expression in brain, and that pharmacological inhibition and genetic deletion of sEH increases bioavailable EETs and are protects against ischemic brain injury. However, the expression profiles of CYP2C11 and sEH in normal brain remain unknown. We demonstrate by immunofluorescence double-labeling that within cerebral parenchymal microvessels, sEH-immunoreactivity (IR) is localized to the vascular smooth muscle layer. Unexpectedly, analysis of large cerebral conduit arteries such as the middle cerebral artery (MCA) revealed CYP2C11 and sEH expression in extrinsic perivascular nerves. Double labeling studies revealed that CYP2C11- and sEH-IR predominantly co-localized with neuronal nitric oxide synthase (nNOS)-IR within perivascular nerve fibers. Significant co-localization for CYP2C11 and sEH was also observed with parasympathetic markers vasoactive intestinal peptide (VIP) and choline actetyltransferase (ChAT), in addition to the sensory fiber markers calcitonin gene-related peptide (CGRP) and substance P. No co-localization was observed for either CYP2C11 or sEH with the sympathetic nerve markers dopamine {beta}-hydroxylase (DBH) or neuropeptide Y (NPY). The presence of enzymes involved in EETs production and inactivation within extrinsic parasympathetic and sensory vasodilator fibers suggests a novel role for EETs in the neurogenic control of cerebral arteries.

Key Words: Brain, Neural, Vascular blood flow







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the The Physiological Society.